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ABSTRACT
Objective To understand belief in a specific scientific
claim by studying the pattern of citations among papers
stating it.
DesignAcompletecitationnetworkwasconstructedfrom
all PubMed indexed English literature papers addressing
the belief that β amyloid, a protein accumulated in the
brain in Alzheimer’s disease, is produced by and injures
skeletal muscle of patients with inclusion body myositis.
Social network theory and graph theory were used to
analyse this network.
MainoutcomemeasuresCitationbias,amplification,and
invention, and their effects on determining authority.
Results The network contained 242 papers and 675
citations addressing the belief, with 220553 citation
pathssupportingit.Unfoundedauthoritywasestablished
by citation bias against papers that refuted or weakened
the belief; amplification, the marked expansion of the
beliefsystemby paperspresentingnodata addressingit;
and forms of invention such as the conversion of
hypothesis into fact through citation alone. Extension of
thisnetworkintotextwithingrantsfundedbytheNational
Institutes of Health and obtained through the Freedom of
Information Act showed the same phenomena present
and sometimes used to justify requests for funding.
ConclusionCitationisbothanimpartialscholarlymethod
and a powerful form of social communication. Through
distortions in its social use that include bias,
amplification, and invention, citation can be used to
generate information cascades resulting in unfounded
authority of claims. Construction and analysis of a claim
specific citation network may clarify the nature of a
publishedbeliefsystemandexposedistortedmethodsof
social citation.
INTRODUCTION
Biomedical knowledge arises from scientific data. The
meansbywhichthisoccurswithinindividualscientific
papers is a generallyaccepted process whereby papers
report rationale, methods, results, and conclusions.
Howanentirebeliefsystemsharedbyascientificcom-
munity ultimately evolves from data across all papers
withinaspecialtyislesswellunderstood.Idescribeand
apply methods for the analysis of such belief systems
using a specific example.
Thebeliefsystemstudiedisthataprotein,βamyloid,
known for its role in injuring brain in Alzheimer’s dis-
ease, is also produced by and injures skeletal muscle
fibres in the muscle disease sporadic inclusion body
myositis. This belief system was chosen for analysis
because of its importance to the care of patients with
inclusion body myositis, as this view seems to be
accepted by many as likely or established fact (at least
200 different journal articles have stated such), with β
amyloid production often reported to be a central ele-
ment in the pathogenesis of the disease (see web extra
note 1), and directs research and treatment trials in the
specialty. The approach taken here was simply to col-
lectallstatementsinthemedicalliteratureonthisbelief
systemandtostudythepatternofcitationamongthem
—thatis,howeachstatementissupportedbyreference
to other papers.
METHODS
The methods are fully described in web extra note 2.
Briefly, queries identified all English language
PubMed indexed articles potentially containing state-
ments pertaining to any of three related molecules (β
amyloid precursor protein, its transcript, or one of its
potential cleaved protein products, β amyloid) and
muscle disease. These 766 papers (see web extra
table 1) were searched for statements addressing the
belief that these molecules are abnormally and specifi-
callypresentinmuscle fibresofpatientswithinclusion
body myositis among many other muscle diseases,
identifying 302 papers
1-302 addressing the broad cate-
gory of “amyloid” and inclusion body myositis of
which 242 papers discussed these specific molecules
(see web extra table 2). I collected all statements
addressing the belief and citations supporting these
statements. Each paper was classified as primary data
(containing experimental data addressing the specific
andabnormalpresenceofthesemoleculesininclusion
bodymyositismuscle),myositisreview(reviewpapers
with the term myositis or the equivalent in their title),
model (reporting cell culture or animal model experi-
ments),orother(allotherpapers).Iclassifiedeachcita-
tionassupportive,neutral,orcriticalaccordingtohow
its underlying statement supported the belief. A net-
work was then constructed representing papers as
nodes and citations as links from one node to another.
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andcitationextractionfor17%ofthepapers,including
all primary data papers.
This citation network was further extended into
research proposals funded by the US National Insti-
tutes of Health, obtained through the Freedom of
InformationActinaccordancewithNationalInstitutes
of Health policy.
This claim specific citation network was then ana-
lysed using graph theory
303 (see methods in web
extra). Briefly, custom MATLAB software (Math-
Works; Natick, MA) and the MatlabBGL package
(written by David Gleich) were used for the analysis
of adjacency matrices representing these networks. A
centralitymeasure
304onthepaperswasdefined(called
thecitationpathindex;similartoothervariantsofcen-
tralitymeasure
305). Authority wasmeasured according
to the method of Kleinberg.
306 Visualisation of net-
works was carried out using Pajek (http://vlado.fmf.
uni-lj.si/pub/networks/pajek/). The maximum likeli-
hood estimate method
307 was implemented in
MATLAB, with code available from www.santafe.
edu/aaronc/powerlaws/.
RESULTS
Authority and belief in a claim specific citation network
The claim that β amyloid and its precursors are abnor-
mally and specifically present in inclusion body myo-
sitis muscle fibres among many other muscle diseases
was studied. The 242 papers containing statements
addressing it (all exact text provided in web extra
table 3) and the 675 citations (not counting duplicates
from one paper to another; see web extra table 4) sup-
portingthesestatementswereusedtoconstructaclaim
specific citation network (fig 1). This network con-
tained 220609 citation paths, with chains of citations
flowing from one paper to the next representing the
entire National Library of Medicine PubMed indexed
discourse on the claim as of 26 October 2007. The his-
torical growth and various mathematical properties
308
of this network are discussed in web extra note 3.
Withinnetworkscertainnodesmayberecognisedas
“authorities,”
306 receiving large amounts of network
traffic. Such authorities can be identified by computa-
tional methods alone through examining the patterns
of connections among the nodes; this is how many
internet search engines identify authoritative web
pages. Because citation is in part an act of communica-
tion within a community of people, social network
theory
309 in particular can be used to analyse it.
Undersocialnetworktheory,authorityofaclaimindi-
cates the community’s net belief about it. Using these
computational methods,
306 four primary data papers,
five model papers, and one review paper constituted
the 10 most authoritative papers. All these papers
expressed the view that the claim was true.
Citation bias against critical primary data
Of the 10 most authoritative papers, four provided
experimental data addressing the claim, reporting the
presenceofthesemoleculesininclusionbodymyositis
muscle fibres.
74757980 All four papers were from the
same laboratory, two of which
7980 probably reported
mostly the same data without citing each other, a
Year
Papers
Citations
2007
= Primary data
= Supportive
= Neutral
= Critical
= Diversion
= Myositis review
= Animal/cell
    culture model
= Other
= Other data
= Authority
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
1996
1995
1994
1993
1992
Critical Supportive
Primary data
Models Other/other data Myositis reviews
Fig 1 | Claim specific citation network. Citations regarding claim that β amyloid precursor protein mRNA or protein, or β amyloid
protein, is abnormally present in inclusion body myositis muscle. The network is organised according to paper category and
year of publication. Authority status (yellow) was defined computationally by network theory. Many citations flow to
supportive primary data but not critical data. Papers are represented as nodes (n=218) and citations as directed edges
(supportive n=636, neutral n=18, critical n=21, diversion n=3). Twenty four papers contain statements pertaining to claim but
do not make or receive citations about it (not shown).
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evidence(seewebextranote4).Majortechnicalweak-
nesses were present in these papers, most notably a
lack of quantitative data as to how many affected mus-
clefibreswereseenanda lackofspecificityofreagents
for distinguishing β amyloid protein from β amyloid
precursor protein (see web extra note 5).
Inspectionofthenetworkdisclosedsixprimarydata
papersthatwererelativelyisolated,receivingnoorfew
citations (fig 1). These papers contained data that
refuted or weakened the claim. Three papers
717377
from independent laboratories reported that in a com-
bined35patientswithinclusionbodymyositisstudied,
28 had no affected muscle fibres while the remaining
seven had five or fewer affected muscle fibres (typical
biopsy sections contain thousands of muscle fibres).
Two papers
7072 by the laboratory that wrote the four
authority papers reported that two of these molecules
(β amyloid precursor protein transcript and protein)
were not specific to inclusion body myositis but were
present in muscle fibres during regeneration in all dis-
eased controls (up to 43 patients in seven disease cate-
gories, including polymyositis, dermatomyositis,
Duchenne muscular dystrophy, and amyotrophic lat-
eral sclerosis). These findings weaken the view that
abnormal amounts of these molecules have any speci-
ficity to inclusion body myositis and that they cause
degeneration of myofibre in patients with inclusion
body myositis. One of these papers reported that all
three molecules, including β amyloid, were produced
by muscle invading macrophages in inclusion body
myositis and all other inflammatory myopathies,
70
offering an alternative source than myofibre produc-
tion for them and indicating that β amyloid was non-
specifically present in other inflammatory myopathy
muscle (see web extra note 6 for a detailed discussion
of these papers).
To understand why supportive but not critical data
achieved authority over the ensuing 12 years since
publication of all of these data, the number of citations
received by each paper was analysed (fig 2). The sup-
portive papers received 94% of the 214 citations to
these primary data, whereas the six papers containing
data that weakened or refuted the claim received only
6% of these citations (differing citation frequency,
P=0.01). Citation bias, here defined as statistically sig-
nificantdifferences in the numberof citations received
among primary data papers, seemed to be specifically
against critical data not the laboratory producing it, as
twopapers
7072thatwerebiasedagainstwerewrittenby
the same research group that wrote four of the highly
cited supportive papers. For example, one of the
papers
70 addresses a crucial question in the specialty,
the relation between inflammation and
degeneration,
1-39 but reported data that potentially
conflicted with the belief that β amyloid is produced
by inclusion body myositis myofibres or is uniquely
present in inclusion body myositis muscle (reporting
thatβamyloidisproducedbymuscleinvadingmacro-
phages in all inflammatory myopathies). These data
have never been cited by their authors despite them
having made 104 citations about β amyloid to other
primary data papers.
Citation bias to justify models
Citation bias has also been used to claim that animal
and cell culture experiments are valid models of inclu-
sionbodymyositis,in17papers.
81-97Ofthe32citations
to primary data from these papers, 31 (97%) flowed to
thefourhighlysupportivepapers,
74757980whereasonly
onecitation(3%)wasmadetoanyofthesixpapersthat
presented data weakening or refuting these as valid
models for inclusion body myositis (fig 3). For exam-
ple, one paper
83 cited another
74 in support of “abnor-
mal accumulation of Aβ-containing inclusions are
present in skeletal muscle of IBM patients” but not
papers that found no
71 or little
7377 β amyloid protein.
Similarly, the same paper
83 cited a paper
75 in support
of “thereisevidence that APP [amyloidprecursor pro-
tein] mRNA levels are selectively enhanced in human
IBM [inclusion body myositis] samples thereby pro-
viding physiological justification for the overexpres-
sion of this protein in transgenic mice,” but not the
paper
73 that found no β amyloid precursor protein
mRNA or the paper,
72 by the same authors as the
paper,
75 that found β amyloid precursor protein
mRNA not “selectively enhanced” in inclusion body
myositisbutpresentinmusclefibresinallothermuscle
diseases examined.The uncited data
72 suggestthat the
animal andcellculture experimentsare nomoremod-
els of inclusion body myositis than any other neuro-
musculardiseaseinwhichmuscleregenerationoccurs.
Citation diversion
Some papers cited content but distorted it. This is not
citation bias, as papers are cited, but rather a different
process called here “citation diversion”—that is, the
citing of content but the altering of its meaning in a
manner that diverts its implications.
One primary data paper
77 reported no β amyloid
precursor protein or β amyloid in three of five patients
withinclusionbody myositisand its presenceinonly a
“few fibres” in the remaining two patients. Three
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Fig 2 | Citation bias against content critical of claim. Shown
are citation frequencies to four authoritative supportive
primary data papers and six primary data papers
70-7577-80
containing data critical of claim
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283738 cited these data (fig 1) reporting that they
“confirmed” the claim (for example, one paper
38 said
“βAPP
7677 in s-IBM fibers has been confirmed by
others”). Whether such data confirm the claim is per-
haps open to interpretation. At the least these data are
exaggeratedandgeneralisedintoaviewthatβamyloid
precursor protein is “accumulated in vacuolated mus-
cle fibers of s-IBM patients
77[other]” as stated by one
paper,
28 supported by an erroneous citation because
three patients in the paper
77 had 1.4% to 5% of their
myofibres vacuolated but all lacked β amyloid precur-
sorprotein.Overtheensuing10years,thesethreesup-
portive citations developed into 7848 supportive
citationpaths—chainsoffalseclaiminthenetworkcre-
ated by citation diversion.
Inanotherexampleofcitationdiversiononepaper
81
stated “Thus, it has been widely accepted that intra-
cellular accumulation of βAPP, Aβ [β amyloid] and
other βAPP proteolytic fragments play an important
role in the pathogenesis of IBM,
8689” although one of
thepapers
89hadnotwidelyacceptedthisclaim,stating
“Aβ-intracellular deposition may be an epiphenome-
non unrelated to myofiber death.”
Amplification through influential papers and citations
Between 1996 and 2007 support for the claim grew
exponentially, withthenumberofsupportivecitations
andcitationpathsincreasingsevenfoldand777-fold,to
636 citations and 220553 citation paths. In contrast,
the critical view grew to only 21 citations and 28 cita-
tion paths (fig 4). No papers refuted or critiqued the
critical data, but instead the data were just ignored.
Analysis of a claim specific citation network can iden-
tify exactlywhich papersand citationshave been most
influential in pushing forward belief
304305 (see web
extra note 7). The increased support was facilitated
by a small number of papers, not reporting any pri-
marydata,throughwhichlargeamountsoftraffic(cita-
tionpaths)flowinthenetwork.Forexample,63%ofall
citation paths (n=139391) flow through one review
paper
21 (compared with 2% of citation paths flowing
through randomly selected other papers); 95% of all
citation paths flow through four review papers
16182137
by the same research group (8% through four ran-
domly selected other papers).
A lens effectwas presentin which a small number of
these influential review papers and model papers con-
taining nodata onclaim validitycollectedand focused
citation (similar to a magnifying lens collecting light)
on particular primary data papers supportive of the
belief, while isolating others that weakened it (fig 4).
Such papers have a network property known as high
betweenness centrality.
304
The term amplification can be used to describe the
expansion of a claim’s belief system by citation to
paperslackinganydataaddressingit,thephenomenon
observed here. Amplification is not inherent to pub-
lished belief systems. Authors could choose to cite
only primary data when making claims, resulting in
amplification minimal networks. Amplification of a
claimis instead introduced into belief systemsthrough
the citing of review papers and other papers that lack
data addressing the claim. Certainly such papers may
be cited for other reasons; amplification only arises
when they are cited to support claims of experimental
results reported elsewhere. (See web extra note 8 for
further discussion of amplification and methods for
quantifying it.)
Network authority emerges through bias against critical
content and amplification
Papers may be biased against for many potential rea-
sons. To examine the role of bias exclusively against
critical content in establishing authority, a simulated
network was constructed in which all statements mak-
ing a supportive claim were amended to recognise cri-
tical views of equivalent content and temporal
availability. Removing bias against critical content
was sufficient to result in authority status for five of
the six infrequently cited primary data papers (fig 4),
indicating that authority status of the claim emerges
from the citation bias against critical content. The
claim cannot be both true and false; the resulting
balanced authority of supportive and refuting papers
indicates that without citation bias there would be
balanced belief in its truth and falseness (see web
extra note 9).
Year
Citations
2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
1996
1995
= Supportive
= Neutral
= Critical
= Animal/cell culture model = Primary data
Supportive data Critical data
1994
1993
1992
Fig 3 | Citations from animal and cell culture model papers to primary data papers supporting
rationale for overproduction of β amyloid precursor protein mRNA as a valid model of inclusion
body myositis. Only one of 32 citations flows to papers
70-737778 that present data that conflict
with the validity of these models
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Distinct from citation bias and amplification, certain
types of fact developed and spread through the belief
system.Theseparticularfactswerenotthosethatarose
from restatement of published claims, but rather
involved different mechanisms either deliberate or
through scholarly negligence, herein called invention.
For example, a subclaim (that the accumulation of β
amyloid occurs early and precedes other abnormal-
ities) has variously been stated as hypothesis, likeli-
hood, or fact in 27 papers supported by 37 citations
(see web extra note 10). Nine of these citations (24%),
usedtosupporttextmakingtheseclaims,infactflowed
to papers that contained no statement on the temporal
relation of β amyloid to other abnormalities in inclu-
sion body myositis muscle (dead end citations). This
subclaim had transformed from hypothesis to “fact”
through citation alone, a process that might be called
citation transmutation (fig 5). Thus one paper
5 con-
tained it as fact (“The appearance of Aβ-positive, non-
congophilic deposits precedes vacuolization in IBM
muscle fibers
80”) supporting this statement by citing
the paper
80 where it had only been proposed as
hypothesis (“may represent early changes of IBM”).
Similarly, another paper
134 reported this as fact (“our
previous studies demonstrated that abnormalities of
βAPP precede other changes including
congophilia
7480141”) even though the cited papers sta-
ted it only as hypothesis
7480 or made no statement at
all
141 about the accumulation of β amyloid precursor
protein preceding other abnormalities.
In another form of invention, claims are introduced
asfactthrougha“backdoor”thatbypassespeerreview
and publication of methods and data. This is accom-
plished by repeated misrepresentation of abstracts as
papers (seven different papers, 17 citations to 12
different misrepresented abstracts; for example, cita-
tion to Neurol 2003;60:333-334, an abstract with cor-
rect listing Neurol 2003;60(suppl 1):A333-4; see web
extra note 11). The claim that “β-amyloid42 isoform
[is] more common than β-amyloid40”
4 is supported in
this manner and accepted by peers as fact (paper 2
states this citing paper 4) (see web extra note 12 for
another form of invention called title invention).
Bias and invention in National Institutes of Health funded
research proposals
Through the publication of scientific papers and the
demonstrationofthesepublicationsasevidenceofpro-
ductivity, the elements of bias, amplification, and
invention can be used indirectly to support requests
for research funding. To determine if these mechan-
isms were used directly to support such requests, the
claim specific citation network was extended from the
PubMed indexed literature into the research sections
and bibliographies of National Institutes of Health
funded grant proposals containing text addressing the
claim,obtainedundertheFreedomofInformationAct
accordingtoNationalInstitutesofHealthpolicy.
310Of
27 grant proposals requested (identified through
searches of the National Institutes of Health CRISP
database as described in web extra note 13), nine
were released by the National Institutes of Health.
These seemed to be the proposals most pertinent to
the belief system.
Citation bias or invention was present in eight of
nine of these proposals (fig 6). Of 23 citations to pri-
mary data (not counting multiple citations from one
proposaltoasinglepaper)addressingtheclaim’svalid-
ity, 20 were made to supportive primary data (19 sup-
portive citations and one neutral citation), two were
instances of citation diversion (one paper
77 again
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Fig 4 | Amplification and authority of claim. (Left) Historical growth of supportive and critical citations in network. (Middle) Rearrangement of network (fig 1) to
visualise a lens effect in which eight key papers (surrounded by ovals; seven by same research group; 97% of all network traffic passes through them) create
citation flows among each other, and both amplify claim and focus citations to supportive data papers. Net effect results in network authority status
306 (yellow)
of supportive data papers. (Right) Computational elimination of citation bias results in balanced authority of both support for claim and its refutation through
additional recognition of critical data papers
70-7377 as authorities
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onewasmadetocriticalcontent.Inventionoffact sup-
ported through citation to hypothesis, dead end cita-
tion, and abstracts misrepresented as papers were
similarly present in these funded proposals. These
were sometimes used directly to justify requests for
funding of the proposed studies (for example, “The
accumulation of epitopes of βAPP is an early event in
the disease relative to the other changes,
3796 justifying
our focused investigation of Aβ”; one paper
37 stated
this only as hypothesis; the other paper
96 stated this
as likelihood not fact, supporting that view also
through citation to the other paper,
37 stated as hypoth-
esis (see web extra note 13 for further discussion).
DISCUSSION
Citation, the act of connecting text statements through
reference to the broader literature, is not simply an
impartial scholarly method for joining related pub-
lishedknowledge.Citationmaybeusedforselfserving
purposes
311orasatoolforpersuasion
312(seewebextra
note 14). These aspects of citation might be called
social citation. I studied how distortions of the persua-
siveaspectofsocial citationmayresultinbroadaccep-
tance of unfounded claims as fact. These distortions
can be detected and interpreted through social net-
worktheory
309becausecitationaspersuasionisasocial
behaviour. Network theory applied to citation net-
works constructed from entire paper bibliographies,
such as the science citation network,
313 can disclose
societal attitudes to journals and specific papers (for
example, impact factors), but these networks are not
suitable for understanding the foundation for belief in
specificclaims.Whennetworksareinsteadconfinedto
citation pertaining to one set of related claims (a claim
specific citation network), they become sharply
focused tools for understanding social communication
pertainingtotheclaims—whatisineffectthepublished
record of a belief system shared by a community.
These allow for study of not just what is said about a
belief (the traditional scope of review papers), but also
who hears it and how it is retold.
The general approach taken here (fig 7) addressed
belief in claims; no experiments were done addressing
their truth. The computational analysis of the claim
specific citation network representing this belief sys-
tem detected certain distortions in the patterns of cita-
tion that would not have been expected had only
scholarly citation been used. Primary data that wea-
kened or refuted claims on which the belief was based
were ignored (citation bias) and a small number of
influential papers and citations exponentially ampli-
fied supportive claim over time without presenting
new primary data (amplification). Certain related
claims were invented as fact. The combined effects of
these citation distortions resulted in authority of the
belief (acceptance of it) according to social network
theory.
There are varied forms and consequences of dis-
torted persuasive citation seen in this study (see box).
Citationbiasagainstcriticalcontentcanbeusedforthe
systematic support of claim,
314 results in the loss of
implications of isolated data (see web extra note 15),
and can be used to justify construction of animal mod-
els, which can then be circularly used to amplify claim
(see web extra note 16). Such animal models have
enormous appeal, and some publications describing
them achieved authority status in this network (fig 1)
Year
Citations
2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
1996
1995
1994
1993
1992
= Primary data = Grant proposal
= Supportive
= Neutral
= Critical
= Diversion
Supportive data Critical data
Fig 6 | Extension of PubMed claim specific citation network
into National Institutes of Health funded research proposals.
Nine funded research grants (G1-G9; see web extra note 13)
contain statements and citations addressing claim; their
citations to primary data are shown. Citation bias and citation
diversion are present
= Hypothesis
= Likelihood
= Fact
= No statement
= Ambiguous
Year
2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
1996
1995
Primary data
1994
1993
1992
Fig 5 | Conversion of hypothesis to fact through citation alone. Citations on statement that
accumulation of β amyloid “precedes” other abnormalities in inclusion body myositis muscle.
Statement as fact is supported through citation to papers that only state it as hypothesis (for
example, references 5 to 80, 91 to 80, 134 to 74) or sometimes supported by citation to
papers that contain no statements addressing it (for example, references 91 to 72, 251 to 75;
dead end citations). This phenomenon might be called citation transmutation (see web extra
note 10 for statements)
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whether these β amyloid related molecules are present
in human inclusion body myositis muscle. Amplifica-
tion involves repetitive citation of review papers or
other papers lacking data, often through self citation,
features noted previously in a variation of a claim spe-
cific citation network.
315 Invention has multiple varia-
tions.
Three factors may account for how citation distor-
tions created authority in this belief system. Foremost
is the power of citation through the choice of which
papers to cite and which to ignore (citation bias), by
citing but distorting content (citation diversion), and
by using citation to invent fact (citation transmutation,
dead end citation, and back door invention).
Second is an inherent property of negative results,
which failed to spread through the network. These
were not repeatedly cited by their authors in subse-
quent papers (only one instance was present
274) as per-
haps there was simply nothing further to say about
them. Unlike “positive results” there is nothing excit-
ing to be repeatedly written about how something was
notfoundinanexperiment.Thustheprogressionfrom
datatoacceptedclaimisdifferentwithinasinglepaper
compared with across many papers in a specialty.
Within a single paper readers generally view new
claims as false until proved true through convincing
methodsand results.Acrossa networkof papers,how-
ever, the barrier to the propagation of negative results
biasesclaimsasbeingviewedastrueuntilprovedfalse.
Thirdly,thisbeliefsystemispossiblyaninformation
cascade (also called an informational cascade),
316317 an
entity resulting when people perceive advantage in
accepting the prevailing view over any private infor-
mation they may have when making choices. Indeed
certain mathematical properties of information cas-
cades (preferential attachment) would be expected to
produce a network with properties seen here (a biased
networkwithapowerlawdistributionofnodedegrees;
see web extra note 3). Many authors may just not be
aware of the critical data, as these data are effectively
isolated from the discourse about this claim and not
mentioned in any review articles. Although unsound
information cascades are in theory fragile and fall
apart quickly when exposed,
316 this may not occur in
biomedical belief systems, where contradicted claims
may persist.
318
Many published biomedical belief systems may be
information cascades because repetition of claims is
ubiquitous in the biomedical literature. Many are
built on sound data, with authors repeating claims
after trusting the published expert opinionof their col-
leagues. However, there are incentives for generating
and joining information cascades regardless of their
soundness. Joining an information cascade aids publi-
cation as articles have to say something and negative
resultsare biasedagainst.
319Generatingandjoiningan
information cascade may improve the likelihood of
obtaining research funding because hypothesis driven
research is an essential requirement
320 at many
research funding agencies such as the National Insti-
tutes of Health, and successful funding generally
requires a “strong hypothesis . . . based on current
scientific literature”
320—that is, the published belief
system of a claim. Chances for successful funding
may therefore be increased through joining the cas-
cade (repeating the claim and proposing experimental
plans around it). In the extension of this citation net-
work into text within grant proposals that have been
funded by the National Institutes of Health, citation
bias, diversion, or invention were often present. Once
research funding has been used to join a cascade there
are further incentives to interpret results through con-
firmation bias (“in a way that confirms one’s precon-
ceptions and to avoid information and interpretations
which contradict prior beliefs”
321) to demonstrate suc-
cess of the research for subsequent funding. Although
joining an information cascade may be an optimal
behaviour for some people, it reduces the likelihood
that future investigators can discover whether it is
sound.
317
Methods for the construction and analysis of com-
prehensive claim specific citation networks present
challenges and limitations. These include interpreting
meaning of text, as people may reasonably interpret
Collect papers
Extract text/citations
Construct network
Amplification Authorities Primary data Invention
Measure citation bias
Compare
Remove citation bias
Balanced authority
Fig 7 | Overview of approach. After construction of the claim specific citation network, a
combined manual and computational endeavour, steps on left (determination of authorities
[yellow papers] and identification of amplification) require only computational algorithms;
right half (identifying which papers contain actual data addressing claim validity and
identifying invention) requires careful reading of paper content. Combining results of authority
identification with data identification allows for recognition of citation bias and subsequent
steps for its simulated removal and assessment of effects on network
RESEARCH
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nomena observed (see web extra note 17 for a discus-
sion of these issues). In principle many biomedical
claims have an associated citation network, the study
of which provides a powerful approach to detecting
citation bias, amplification, and invention, and under-
standing the nature of the authority of the claim.
I thank Daniel Rockmore (Department of Mathematics, Dartmouth
College); Daniel Jonah Goldhagen; Peter Park (Harvard Medical School);
and Einer Elhauge (Harvard Law School), for thoughtful discussions.
Anthony Amato (Harvard Medical School) carried out validation of
extracted text and citations.
Funding: SAG is in part supported by National Institutes of Health grants
R01NS43471 and R21NS057225, and Muscular Dystrophy Association
grant MDA4353. These grants did not contain specific aims directly
encompassing this research.
Competing interests: SAG had full access to all of the data in the study
and takes responsibility for the integrity of the data and the accuracy of
the data analysis.
Ethical approval: Not required.
1 Needham M, Mastaglia FL. Inclusion body myositis: current
pathogenetic concepts and diagnostic and therapeutic approaches.
Lancet Neurol 2007;6:620-631.
2 Needham M, Mastaglia FL, Garlepp MJ. Genetics of inclusion-body
myositis. Muscle Nerve 2007;35:549-561.
3 Askanas V, Engel WK. Inclusion-body myositis, a multifactorial
muscle disease associated with aging: current concepts of
pathogenesis. Curr Opin Rheumatol 2007;19:550-559.
4 Askanas V, Engel WK. Inclusion-body myositis: a myodegenerative
conformational disorder associated with Abeta, protein misfolding,
and proteasome inhibition. Neurology 2006;66(2 Suppl 1):S39-48.
5 Murphy MP, Golde TE. Inclusion-body myositis and Alzheimer
disease: two sides of the same coin, or different currencies
altogether? Neurology 2006;66(2 Suppl 1):S65-68.
6 Buxbaum JN. Treatment and prevention of the amyloidoses: can the
lessons learned be applied to sporadic inclusion-body myositis?
Neurology 2006;66(2 Suppl 1):S110-113.
7 Engel WK, Askanas V. Inclusion-body myositis: clinical, diagnostic,
and pathologic aspects. Neurology 2006;66(2 Suppl 1):S20-29.
8 Dalakas MC. Inflammatory, immune, and viral aspects of inclusion-
body myositis. Neurology 2006;66(2 Suppl 1):S33-38.
9 Dalakas MC. Sporadic inclusion body myositis–diagnosis,
pathogenesis and therapeutic strategies. Nat Clin Pract Neurol
2006;2:437-447.
10 Munshi SK,Thanvi B,Jonnalagadda SJ etal. Inclusionbody myositis:
an underdiagnosed myopathy of older people. Age Ageing
2006;35:91-94.
11 Askanas V, Engel WK. Molecular pathology and pathogenesis of
inclusion-body myositis. Microsc Res Tech 2005;67:114-120.
12 Askanas V, Engel WK. Sporadic inclusion-body myositis: a proposed
key pathogenetic role of the abnormalities of the ubiquitin-
proteasome system, and protein misfolding and aggregation. Acta
Myol 2005;24:17-24.
13 Oldfors A, Lindberg C. Diagnosis, pathogenesis and treatment of
inclusion body myositis. Curr Opin Neurol 2005;18:497-503.
14 Dalakas MC. Inflammatory disorders of muscle: progress in
polymyositis, dermatomyositis and inclusion body myositis. Curr
Opin Neurol 2004;17:561-567.
15 Askanas V, Engel WK. Unfolding storyof inclusion-bodymyositis and
myopathies: role of misfolded proteins, amyloid-beta, cholesterol,
and aging. J Child Neurol 2003;18:185-190.
16 Askanas V, Engel WK. Proposed pathogenetic cascade of inclusion-
body myositis: importance of amyloid-beta, misfolded proteins,
predisposing genes, and aging. Curr Opin Rheumatol
2003;15:737-744.
17 Dalakas MC. Understanding the immunopathogenesis of inclusion-
body myositis: present and future prospects. R e vN e u r o l( P a r i s )
2002;158:948-958.
18 Askanas V, Engel WK. Inclusion-body myositis and myopathies:
different etiologies, possibly similar pathogenic mechanisms. Curr
Opin Neurol 2002;15:525-531.
19 Tawil R, Griggs RC. Inclusion body myositis. Curr Opin Rheumatol
2002;14:653-657.
20 Askanas V, Engel WK. Newest pathogenetic considerations in
inclusion-body myositis: possible role of amyloid-beta, cholesterol,
relation to aging and to Alzheimer’sd i s e a s e .Curr Rheumatol Rep
2002;4:427-433.
21 Askanas V, Engel WK. Inclusion-body myositis: newest concepts of
pathogenesis and relation to aging and Alzheimer disease. J
Neuropathol Exp Neurol 2001;60:1-14.
22 O l d f o r sA ,F y h rI M .I n c l u s i o nb o d ym y o s i t i s :g e n e t i cf a c t o r s ,a b e r r a n t
protein expression, and autoimmunity. Curr Opin Rheumatol
2001;13:469-475.
23 Oldfors A, Lindberg C. Inclusion body myositis. Curr Opin Neurol
1999;12:527-533.
24 CherinP. Treatmentofinclusionbody myositis. CurrOpinRheumatol
1999;11:456-461.
WHAT IS ALREADY KNOWN ON THIS TOPIC
In addition to its scholarly use, citation has social uses, both self serving and as a tool for
persuasion
One distortion of this persuasive aspect of citation, citation bias, has been recognised in
clinical trial reporting where it may lead to false belief about a therapy’se f f i c a c y
WHAT THIS STUDY ADDS
Distortions in the persuasive use of citation—bias, amplification, and invention—can be
used to establish unfounded scientific claims as fact
Categorising these distorted uses of citation and having vocabulary for them aids in their
recognition
How scientific data evolve into entire published biomedical belief systems around specific
claimscanbestudiedthroughadevicecalledaclaimspecificcitationnetworkandtheuseof
social network theory
Vocabulary of citation distortions
Citation
Both scholarly and social forms: the scholarly form connects statements to the broader
medical literature, the social form (social citation) includes self serving and persuasive
subtypes
Citation distortions
Self serving citation is always a distortion
Persuasive citation may be necessary to communicate new, sound claims to the scientific
community; it may, however, have distorted uses—citation bias, amplification, and
invention
Citation bias
Systematic ignoring of papers that contain content conflicting with a claim
Bolster claim; justifying animal models to provide opportunities to amplify claim
Amplification
Expansion of a belief system without data
Citation made to papers that don’t contain primary data, increasing the number of
citations supporting the claim without presenting data addressing it
Invention
Citation diversion—citing contentbut claiming ithasa differentmeaning, thereby diverting
its implications
Citation transmutation—the conversion of hypothesis into fact through the act of citation
alone
Back door invention—repeated misrepresentation of abstracts as peer reviewed papers to
fool readers into believing that claimsarebased on peer reviewed published methodsand
data
Dead end citation—support of a claim with citation to papers that do not contain content
addressing the claim
Titleinvention—reportingof “experimentalresults”in apaper’stitle, eventhoughthepaper
does not report the performance or results of any such experiments
RESEARCH
page 8 of 14 BMJ | ONLINE FIRST | bmj.com25 Vogel H. Inclusion body myositis–a review. Adv Anat Pathol
1998;5:164-169.
26 Askanas V, Engel WK. Sporadic inclusion-body myositis and
hereditaryinclusion-bodymyopathies:currentconceptsofdiagnosis
and pathogenesis. Curr Opin Rheumatol 1998;10:530-542.
27 Askanas V, Engel WK. Does overexpression of betaAPP in aging
muscle have a pathogenic role and a relevance to Alzheimer’s
disease? Clues from inclusion body myositis, cultured human
muscle, and transgenic mice. Am J Pathol 1998;153:1673-1677.
28 Askanas V, Engel WK. Sporadic inclusion-body myositis and its
similarities to Alzheimer disease brain. Recent approaches to
diagnosis and pathogenesis, and relation to aging. Scand J
Rheumatol 1998;27:389-405.
29 Askanas V, Engel WK. Sporadic inclusion-body myositis and
hereditary inclusion-body myopathies: diseases of oxidative stress
and aging? Arch Neurol 1998;55:915-920.
30 Askanas V, Engel WK, Alvarez RB. Fourteen newly recognized
proteins at the human neuromuscular junctions–and their
nonjunctional accumulation in inclusion-body myositis. Ann N Y
Acad Sci 1998;841:28-56.
31 IllaI,DalakasMC.Dermatomyositis,polymyositisandinclusionbody
myositis: current concepts. Rev Neurol (Paris) 1998;154:13-16.
32 Sivakumar K, Dalakas MC. Inclusion body myositis and myopathies.
Curr Opin Neurol 1997;10:413-420.
33 Dalakas MC, Sivakumar K. The immunopathologic and inflammatory
differences between dermatomyositis, polymyositis and sporadic
inclusion body myositis. Curr Opin Neurol 1996;9:235-239.
34 Garlepp MJ, Mastaglia FL. Inclusion body myositis. JN e u r o l
Neurosurg Psychiatry 1996;60:251-255.
35 Carpenter S. Inclusion body myositis, a review. J Neuropathol Exp
Neurol 1996;55:1105-1114.
36 Griggs RC, Askanas V, DiMauro S et al. Inclusion body myositis and
myopathies. Ann Neurol 1995;38:705-713.
37 Askanas V, Engel WK. New advances in the understanding of
sporadic inclusion-body myositis and hereditary inclusion-body
myopathies. Curr Opin Rheumatol 1995;7:486-496.
38 Askanas V, Engel WK, Mirabella M. Idiopathic inflammatory
myopathies: inclusion-body myositis, polymyositis, and
dermatomyositis. Curr Opin Neurol 1994;7:448-456.
39 Calabrese LH, Chou SM. Inclusion body myositis. Rheum Dis Clin
North Am 1994;20:955-972.
40 Chou SM. Inclusion body myositis. Baillieres Clin Neurol
1993;2:557-577.
41 AskanasV,EngelWK.Newadvancesininclusion-bodymyositis.Curr
Opin Rheumatol 1993;5:732-741.
42 Sekul EA, Dalakas MC. Inclusion body myositis: new concepts.
Semin Neurol 1993;13:256-263.
43 Briani C, Doria A, Sarzi-Puttini P, Dalakas MC. Update on idiopathic
inflammatory myopathies. Autoimmunity 2006;39:161-170.
44 Dalakas MC. Therapeutic targets in patients with inflammatory
myopathies: present approaches and a look to the future.
Neuromuscul Disord 2006;16:223-236.
45 Dalakas MC. Mechanisms of disease: signaling pathways and
immunobiology of inflammatory myopathies. Nat Clin Pract
Rheumatol 2006;2:219-227.
46 DalakasMC.Thefutureprospectsintheclassification,diagnosisand
therapies of inflammatory myopathies: a view to the future from the
“bench-to-bedside”. JN e u r o l2004;251:651-657.
47 Chinoy H, Ollier WE, Cooper RG. Have recent immunogenetic
investigations increased our understanding of disease mechanisms
in the idiopathic inflammatory myopathies? Curr Opin Rheumatol
2004;16:707-713.
48 Christopher-Stine L, Plotz PH. Myositis: an update on pathogenesis.
Curr Opin Rheumatol 2004;16:700-706.
49 Christopher-Stine L, Plotz PH. Adult inflammatory myopathies. Best
Pract Res Clin Rheumatol 2004;18:331-344.
50 Dalakas MC. The molecular pathophysiology in inflammatory
myopathies. Rev Med Interne 2004;25 Suppl 1:S14-16.
51 Figarella-Branger D, Civatte M, Bartoli C, Pellissier JF. Cytokines,
chemokines, and cell adhesion molecules in inflammatory
myopathies. Muscle Nerve 2003;28:659-682.
52 Mastaglia FL, Garlepp MJ, Phillips BA, Zilko PJ. Inflammatory
myopathies: clinical, diagnostic and therapeutic aspects. Muscle
Nerve 2003;27:407-425.
53 Dalakas MC. Therapeutic approaches in patients with inflammatory
myopathies. Semin Neurol 2003;23:199-206.
54 Dalakas MC. Muscle biopsy findings in inflammatory myopathies.
Rheum Dis Clin North Am 2002;28:779-798.
55 Kissel JT. Misunderstandings, misperceptions, and mistakes in the
management of the inflammatory myopathies. Semin Neurol
2002;22:41-51.
56 Hilton-Jones D. Inflammatory muscle diseases. Curr Opin Neurol
2001;14:591-596.
57 Dalakas MC. Molecular immunology and genetics of inflammatory
muscle diseases. Arch Neurol 1998;55:1509-1512.
58 Bertorini TE. Inflammatory myopathies [polymyositis,
dermatomyositis, inclusion body myositis]. Compr Ther
1998;24:494-502.
59 MantegazzaR,BernasconiP,ConfalonieriP,CornelioF.Inflammatory
myopathies and systemic disorders: a review of
immunopathogenetic mechanisms and clinical features. JN e u r o l
1997;244:277-287.
60 Amato AA, Barohn RJ. Idiopathic inflammatory myopathies. Neurol
Clin 1997;15:615-648.
61 Serratrice G. The three groups of polymyositis. Rev Rhum Engl Ed
1996;63:797-800.
62 Dalakas MC. Immunopathogenesis of inflammatory myopathies.
Ann Neurol 1995;37(suppl 1):S74-S86.
63 Mantegazza R, Bernasconi P. Cellular aspects of myositis. Curr Opin
Rheumatol 1994;6:568-574.
64 DalakasMC.Currenttreatmentoftheinflammatorymyopathies.Curr
Opin Rheumatol 1994;6:595-601.
65 Karpati G, Carpenter S. Pathology of the inflammatory myopathies.
Baillieres Clin Neurol 1993;2:527-556.
66 Dalakas MC. Clinical, immunopathologic, and therapeutic
considerations of inflammatory myopathies. Clin Neuropharmacol
1992;15:327-351.
67 Kalovidouris AE. Immune aspects of myositis. Curr Opin Rheumatol
1992;4:809-814.
68 Dalakas MC. Inflammatory and toxic myopathies. Curr Opin Neurol
Neurosurg 1992;5:645-654.
69 Lunemann JD, Schmidt J, Schmid D et al. Beta-amyloid is a substrate
of autophagy in sporadic inclusion body myositis. Ann Neurol
2007;61:476-483.
70 Askanas V, Sarkozi E, Bilak M et al. Human muscle macrophages
expressbeta-amyloidprecursor andprion proteins andtheirmRNAs.
Neuroreport 1995;6:1045-1049.
71 Sherriff FE, Joachim CL, Squier MV, Esiri MM. Ubiquitinated
inclusions in inclusion-body myositis patients are immunoreactive
forcathepsinDbutnotbeta-amyloid.NeurosciLett1995;194:37-40.
72 Sarkozi E, Askanas V, Johnson SA et al. Expression of beta-amyloid
precursor protein gene is developmentally regulated in human
muscle fibers in vivo and in vitro. Exp Neurol 1994;128:27-33.
73 Nalbantoglu J, Karpati G, Carpenter S. Conspicuous accumulation of
a single-stranded DNA binding protein in skeletal muscle fibers in
inclusion body myositis. Am J Pathol 1994;144:874-882.
74 AskanasV,AlvarezRB,EngelWK.beta-Amyloidprecursorepitopesin
muscle fibers of inclusion body myositis. Ann Neurol
1993;34:551-560.
75 Sarkozi E, Askanas V, Johnson SA et al. beta-Amyloid precursor
protein mRNA is increased in inclusion-body myositis muscle.
Neuroreport 1993;4:815-818.
76 Villanova M, Kawai M, Lubke U et al. Rimmed vacuoles of inclusion
body myositis and oculopharyngeal muscular dystrophy contain
amyloid precursor protein and lysosomal markers. Brain Res
1993;603:343-347.
77 Leclerc A, Tome FM, Fardeau M. Ubiquitin and beta-amyloid-protein
in inclusion body myositis (IBM), familial IBM-like disorder and
oculopharyngeal muscular dystrophy: an immunocytochemical
study. Neuromuscul Disord 1993;3:283-291.
78 Schubert W, Masters CL, Beyreuther K. APP+ T lymphocytes
selectively sorted to endomysial tubes in polymyositis displace
NCAM-expressing muscle fibers. Eur J Cell Biol 1993;62:333-342.
79 Askanas V, Engel WK, Alvarez RB, Glenner GG. beta-Amyloid protein
immunoreactivityinmuscleofpatientswithinclusion-bodymyositis.
Lancet 1992;339:560-561.
80 Askanas V, Engel WK, Alvarez RB. Light and electron microscopic
localization of beta-amyloid protein in muscle biopsies of patients
with inclusion-body myositis. Am J Pathol 1992;141:31-36.
81 Sugarman MC, Kitazawa M, Baker M et al. Pathogenic accumulation
of APP in fast twitch muscle of IBM patients and a transgenic model.
Neurobiol Aging 2006;27:423-432.
82 Rosen KM, Veereshwarayya V, Moussa CE et al. Parkin protects
against mitochondrial toxins and beta-amyloid accumulation in
skeletal muscle cells. JB i o lC h e m2006;281:12809-12816.
83 Kitazawa M, Green KN, Caccamo A, LaFerla FM. Genetically
augmentingAbeta42levelsinskeletalmuscleexacerbatesinclusion
body myositis-like pathology and motor deficits in transgenic mice.
Am J Pathol 2006;168:1986-1997.
84 MoussaCE,FuQ,KumarPetal.Transgenicexpressionofbeta-APPin
fast-twitch skeletal muscle leads to calcium dyshomeostasis and
IBM-like pathology. Faseb J 2006;20:2165-2167.
85 Fratta P, Engel WK, McFerrin J et al. Proteasome inhibition and
aggresome formation in sporadic inclusion-body myositis and in
amyloid-beta precursor protein-overexpressing cultured human
muscle fibers. Am J Pathol 2005;167:517-526.
86 Christensen RA, Shtifman A, Allen PD et al. Calcium dyshomeostasis
in beta-amyloid and tau-bearing skeletal myotubes. JB i o lC h e m
2004;279:53524-53532.
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 9 of 1487 Strazielle C, Dumont M, Fukuchi K, Lalonde R. Transgenic mice
expressing the human C99 terminal fragment of betaAPP: effects on
cytochrome oxidase activity in skeletal muscle and brain. J Chem
Neuroanat 2004;27:237-246.
88 Sugarman MC, Yamasaki TR, Oddo S et al. Inclusion body myositis-
like phenotype induced by transgenic overexpression of beta APP in
skeletal muscle. Proc Natl Acad Sci U S A 2002;99:6334-6339.
89 Querfurth HW, Suhara T, Rosen KM et al. Beta-amyloid peptide
expression is sufficient for myotube death: implications for human
inclusion body myopathy. M o lC e l lN e u r o s c i2001;17:793-810.
90 Baron P, Galimberti D, Meda L et al. Production of IL-6 by human
myoblasts stimulated with Abeta: relevance in the pathogenesis of
IBM. Neurology 2001;57:1561-1565.
91 BaronP,GalimbertiD,MedaLetal.Synergisticeffectofbeta-amyloid
protein and interferon gamma on nitric oxide production by C2C12
muscle cells. Brain 2000;123:374-379.
92 McFerrin J, Engel WK, Askanas V. Cultured inclusion-body myositis
musclefibersdonotaccumulatebeta-amyloidprecursorproteinand
can be innervated. Neurology 1999;53:2184-2187.
93 Fukuchi K, Pham D, Hart M et al. Amyloid-beta deposition in skeletal
muscle of transgenic mice: possible model of inclusion body
myopathy. Am J Pathol 1998;153:1687-1693.
94 Jin LW, Hearn MG, Ogburn CE et al. Transgenic mice over-expressing
the C-99 fragment of betaPP with an alpha-secretase site mutation
develop a myopathy similar to human inclusion body myositis. Am J
Pathol 1998;153:1679-1686.
95 McFerrin J, Engel WK, Askanas V. Impaired innervation of cultured
human muscle overexpressing betaAPP experimentally and
genetically: relevance to inclusion-body myopathies. Neuroreport
1998;9:3201-3205.
96 Askanas V, McFerrin J, Alvarez RB et al. Beta APP gene transfer into
cultured human muscle induces inclusion-body myositis aspects.
Neuroreport 1997;8:2155-2158.
97 Askanas V, McFerrin J, Baque S et al. Transfer of beta-amyloid
precursor protein gene using adenovirus vector causes
mitochondrial abnormalities incultured normal humanmuscle. Proc
Natl Acad Sci U S A 1996;93:1314-1319.
98 Banwell BL, Engel AG. AlphaB-crystallin immunolocalization yields
new insights into inclusion body myositis. Neurology
2000;54:1033-1041.
99 Hutchinson DO. Inclusion body myositis: abnormal protein
accumulation does not trigger apoptosis. Neurology
1998;51:1742-1745.
100 Pruitt JN, 2nd, Showalter CJ, Engel AG. Sporadic inclusion body
myositis: counts of different types of abnormal fibers. Ann Neurol
1996;39:139-143.
101 Askanas V, Engel WK, Alvarez RB. Enhanced detection of congo-red-
positiveamyloiddepositsinmusclefibersofinclusionbodymyositis
and brain of Alzheimer’s disease using fluorescence technique.
Neurology 1993;43:1265-1267.
102 Mendell JR, Sahenk Z. Inclusion body myositis. Neurology
1992;42:2231-2232.
103 Neville HE, Baumbach LL, Ringel SP et al. Familial inclusion body
myositis: evidence for autosomal dominant inheritance. Neurology
1992;42:897-902.
104 Mendell JR, Sahenk Z, Gales T, Paul L. Amyloid filaments in inclusion
body myositis. Novel findings provide insight into nature of
filaments. Arch Neurol 1991;48:1229-1234.
105 Wojcik S, Nogalska A, McFerrin J et al. Myostatin precursor protein is
increased and associates with amyloid-beta precursor protein in
inclusion-body myositis culture model. Neuropathol Appl Neurobiol
2007;33:238-242.
106 Wojcik S, Engel WK, Yan R et al. NOGO is increased and binds to
BACE1 in sporadic inclusion-body myositis and in AbetaPP-
overexpressing cultured human muscle fibers. Acta Neuropathol
(Berl) 2007;114:517-526.
107 Salajegheh M, Raju R, Schmidt J, Dalakas MC. Upregulation of
thrombospondin-1(TSP-1) and itsbindingpartners,CD36 and CD47,
in sporadic inclusion body myositis. JN e u r o i m m u n o l
2007;187:166-174.
108 Wojcik S, Engel WK, McFerrin J et al. AbetaPP-overexpression and
proteasome inhibition increase alphaB-crystallin in cultured human
muscle: relevance to inclusion-body myositis. Neuromuscul Disord
2006;16:839-844.
109 Paciello O, Wojcik S, Engel WK et al. Parkin and its association with
alpha-synuclein and AbetaPP in inclusion-body myositis and
AbetaPP-overexpressing cultured human muscle fibers. Acta Myol
2006;25:13-22.
110 Nogalska A, Engel WK, McFerrin J et al. Homocysteine-induced
endoplasmic reticulum protein (Herp) is up-regulated in sporadic
inclusion-body myositis and in endoplasmic reticulum stress-
induced cultured human muscle fibers. J Neurochem
2006;96:1491-1499.
111 Broccolini A, Gidaro T, Morosetti R et al. Neprilysin participates in
skeletal muscle regeneration and is accumulated in abnormal
muscle fibres of inclusion body myositis. J Neurochem
2006;96:777-789.
112 Li J, Yin C, Okamoto H et al. Proteomic analysis of inclusion body
myositis. J Neuropathol Exp Neurol 2006;65:826-833.
113 Wojcik S, Engel WK, McFerrin J, Askanas V. Myostatin is increased
and complexes with amyloid-beta within sporadic inclusion-body
myositis muscle fibers. Acta Neuropathol (Berl) 2005;110:173-177.
114 Ferrer I, Carmona M, Blanco R et al. Involvement of clusterin and the
aggresome in abnormal protein deposits in myofibrillar myopathies
and inclusion body myositis. Brain Pathol 2005;15:101-108.
115 FrattaP,EngelWK,VanLeeuwenFW etal. MutantubiquitinUBB+1is
accumulated in sporadic inclusion-body myositis muscle fibers.
Neurology 2004;63:1114-1117.
116 Broccolini A, Ricci E, Pescatori M et al. Insulin-like growth factor I in
inclusion-body myositis and human muscle cultures. JN e u r o p a t h o l
Exp Neurol 2004;63:650-659.
117 Vattemi G, Engel WK, McFerrin J, Askanas V. Endoplasmic reticulum
stress and unfolded protein response in inclusion body myositis
muscle. Am J Pathol 2004;164:1-7.
118 ChoiYC,KimTS,KimSY.Increaseintransglutaminase2inidiopathic
inflammatory myopathies. Eur Neurol 2004;51:10-14.
119 Vattemi G, Engel WK, McFerrin J, Askanas V. Cystatin C colocalizes
with amyloid-beta and coimmunoprecipitates with amyloid-beta
precursor protein in sporadic inclusion-body myositis muscles. J
Neurochem 2003;85:1539-1546.
120 Jaworska-Wilczynska M, Wilczynski GM, Engel WK et al. Three
lipoprotein receptors and cholesterol in inclusion-body myositis
muscle. Neurology 2002;58:438-445.
121 Greenberg SA, Sanoudou D, Haslett JN et al. Molecular profiles of
inflammatory myopathies. Neurology 2002;59:1170-1182.
122 Vattemi G, Engel WK, McFerrin J et al. Presence of BACE1 and BACE2
in muscle fibres of patients with sporadic inclusion-body myositis.
Lancet 2001;358:1962-1964.
123 Wilczynski GM, Engel WK, Askanas V. Novel cytoplasmic
immunolocalization of RNA polymerase II in inclusion-body myositis
muscle. Neuroreport 2001;12:1809-1814.
124 Zanusso G, Vattemi G, Ferrari S et al. Increased expression of the
normal cellular isoform of prion protein in inclusion-body myositis,
inflammatory myopathies and denervation atrophy. Brain Pathol
2001;11:182-189.
125 Choi Y-C, Park GT, Kim T-S et al. Sporadic inclusion body myositis
correlates with increased expression and cross-linking by
transglutaminases 1 and 2. J. Biol. Chem 2000;275:8703-8710.
126 Choi YC,DalakasMC. Expression of matrixmetalloproteinases in the
muscle of patients with inflammatory myopathies. Neurology
2000;54:65-71.
127 Wilczynski GM, Engel WK, Askanas V. Cyclin-dependent kinase 5
colocalizes with phosphorylated tau in human inclusion-body
myositis paired-helical filaments and may play a role in tau
phosphorylation. Neurosci Lett 2000;293:33-36.
128 Kok CC, Boyt A, Gaudieri S et al. Mitochondrial DNA variants in
inclusion body myositis. Neuromuscul Disord 2000;10:604-611.
129 Askanas V, Engel WK, Alvarez RB et al. Novel immunolocalization of
alpha-synuclein in human muscle of inclusion-body myositis,
regenerating and necrotic muscle fibers, and at neuromuscular
junctions. J Neuropathol Exp Neurol 2000;59:592-598.
130 Wilczynski GM, Engel WK, Askanas V. Association of active
extracellular signal-regulated protein kinase with paired helical
filaments of inclusion-body myositis muscle suggests its role in
inclusion-body myositis tau phosphorylation. Am J Pathol
2000;156:1835-1840.
131 Broccolini A, Engel WK, Alvarez RB, Askanas V. Redox factor-1 in
muscle biopsies of patients with inclusion-body myositis. Neurosci
Lett 2000;287:1-4.
132 Li M, Dalakas MC. The muscle mitogen-activated protein kinase is
altered in sporadic inclusion body myositis. Neurology
2000;54:1665-1670.
133 Broccolini A, Engel WK, Alvarez RB, Askanas V. Paired helical
filaments of inclusion-body myositis muscle contain RNA and
survival motor neuron protein. Am J Pathol 2000;156:1151-1155.
134 Askanas V, Engel WK, Yang CC et al. Light and electron microscopic
immunolocalization of presenilin 1 in abnormal muscle fibers of
patients with sporadic inclusion-body myositis and autosomal-
recessiveinclusion-bodymyopathy.AmJPathol1998;152:889-895.
135 Yang CC, Askanas V, Engel WK, Alvarez RB. Immunolocalization of
transcription factor NF-kappaB in inclusion-body myositis muscle
and at normal human neuromuscular junctions. Neurosci Lett
1998;254:77-80.
136 Semino-Mora C, Dalakas MC. Rimmed vacuoles with beta-amyloid
and ubiquitinated filamentous deposits in the muscles of patients
with long-standing denervation (postpoliomyelitis muscular
atrophy): similarities with inclusion body myositis. Hum Pathol
1998;29:1128-1133.
RESEARCH
page 10 of 14 BMJ | ONLINE FIRST | bmj.com137 Yang CC, Alvarez RB, Engel WK, Askanas V. Increase of nitric oxide
synthases and nitrotyrosine in inclusion-body myositis. Neuroreport
1996;8:153-158.
138 Mirabella M, Alvarez RB, Engel WK et al. Apolipoprotein E and
apolipoprotein E messenger RNA in muscle of inclusion body
myositis and myopathies. Ann Neurol 1996;40:864-872.
139 Sarkozi E, Askanas V, Engel WK. Abnormal accumulation of prion
protein mRNA in muscle fibers of patients with sporadic inclusion-
body myositis and hereditary inclusion-body myopathy. Am J Pathol
1994;145:1280-1284.
140 Askanas V, Mirabella M, Engel WK et al. Apolipoprotein E
immunoreactive deposits in inclusion-body muscle diseases. Lancet
1994;343:364-365.
141 Askanas V, Engel WK, Bilak M et al. Twisted tubulofilaments of
inclusion body myositis muscle resemble paired helical filaments of
Alzheimer brain and contain hyperphosphorylated tau. Am J Pathol
1994;144:177-187.
142 Askanas V, Bilak M, Engel WK et al. Prion protein is abnormally
accumulated in inclusion-body myositis. Neuroreport
1993;5:25-28.
143 Bilak M, Askanas V, Engel WK. Strong immunoreactivity of alpha 1-
antichymotrypsin co-localizes with beta-amyloid protein and
ubiquitin in vacuolated muscle fibers of inclusion-body myositis.
Acta Neuropathol (Berl) 1993;85:378-382.
144 Greenberg SA. A gene expression approach to study perturbed
pathways in myositis. Curr Opin Rheumatol 2007;19:536-541.
145 Kimonis VE, Watts GD. Autosomal dominant inclusion body
myopathy, Paget disease of bone, and frontotemporal dementia.
Alzheimer Dis Assoc Disord 2005;19 Suppl 1:S44-47.
146 Nogalska A, Wojcik S, Engel WK et al. Endoplasmic reticulum stress
induces myostatin precursor protein and NF-kappaB in cultured
human muscle fibers: relevance to inclusion body myositis. Exp
Neurol 2007;204:610-618.
147 Malicdan MC, Noguchi S, Nonaka I et al. A GNE knockout mouse
expressing human V572L mutation develops features similar to
distal myopathy with rimmed vacuoles or hereditary inclusion body
myopathy. Hum Mol Genet 2007;16:115-128.
148 Morosetti R, Mirabella M, Gliubizzi C et al. MyoD expression restores
defective myogenic differentiation of human mesoangioblasts from
inclusion-body myositis muscle. Proc Natl Acad Sci U S A
2006;103:16995-17000.
149 Chahin N, Engel AG. Correlation of muscle biopsy, clinical course,
and outcome in PM and sporadic IBM. Neurology 2008;70:418-24.
150 HuangS,LiangJ,ZhengMetal.Inducibleoverexpressionofwild-type
prion protein in the muscles leads to a primary myopathy in
transgenic mice. Proc Natl Acad Sci U S A 2007;104:6800-6805.
151 Dalakas MC, Rakocevic G, Shatunov A et al. Inclusion body myositis
withhumanimmunodeficiencyvirusinfection:fourcaseswithclonal
expansion of viral-specific T cells. Ann Neurol 2007;61:466-475.
152 Hadjivassiliou M, Chattopadhyay AK, Grunewald RA et al. Myopathy
associated with gluten sensitivity. Muscle Nerve 2007;35:443-450.
153 Weihl CC, Miller SE, Hanson PI, Pestronk A. Transgenic expression of
inclusion body myopathy associated mutant p97/VCP causes
weakness and ubiquitinated protein inclusions in mice. Hum Mol
Genet 2007;16:919-928.
154 Hatanaka Y, Oh SJ. Single-fiber electromyography in sporadic
inclusion body myopathy. Clin Neurophysiol 2007;118:1563-1568.
155 FinchCE.Aperspectiveonsporadicinclusion-bodymyositis:therole
of aging and inflammatory processes. Neurology
2006;66(2 Suppl 1):S1-6.
156 Glabe CG, Kayed R. Common structure and toxic function of amyloid
oligomers implies a common mechanism of pathogenesis.
Neurology 2006;66(2 Suppl 1):S74-78.
157 VetrivelKS,ThinakaranG.Amyloidogenicprocessingofbeta-amyloid
precursor protein in intracellular compartments. Neurology
2006;66(2 Suppl 1):S69-73.
158 Moreira PI, Honda K, Zhu X et al. Brain and brawn: parallels in
oxidative strength. Neurology 2006;66(2 Suppl 1):S97-101.
159 Zhang K, Kaufman RJ. The unfolded protein response: a stress
signaling pathway critical for health and disease. Neurology
2006;66(2 Suppl 1):S102-109.
160 Koistinen H, Prinjha R, Soden P et al. Elevated levels of amyloid
precursor protein in muscle of patients with amyotrophic lateral
sclerosis and a mouse model of the disease. Muscle Nerve
2006;34:444-450.
161 Fidzianska A, Glinka Z. Rimmed vacuoles with beta-amyloid and tau
protein deposits in the muscle of children with hereditary myopathy.
Acta Neuropathol (Berl) 2006;112:185-193.
162 Dimitri D, Benveniste O, Dubourg O et al. Shared blood and muscle
CD8+ T-cell expansions in inclusion body myositis. Brain
2006;129:986-995.
163 McGavern DB. Immunotherapeutic relief from persistent infections
and amyloid disorders. Neurology 2006;66(2 Suppl 1):S59-64.
164 Steinman L. Controlling autoimmunity in sporadic inclusion-body
myositis. Neurology 2006;66(2 Suppl 1):S56-58.
165 OldforsA,MoslemiAR,JonassonLetal.Mitochondrialabnormalities
in inclusion-body myositis. Neurology 2006;66(2 Suppl 1):S49-55.
166 Ghetti B, Goebel HH. Frontotemporal dementia: the post-tau era.
Neurology 2006;67:560-561.
167 Weihl CC, Dalal S, Pestronk A, Hanson PI. Inclusion body myopathy-
associated mutations in p97/VCP impair endoplasmic reticulum-
associated degradation. Hum Mol Genet 2006;15:189-199.
168 De Bleecker JL, Creus KK, De Paepe B. Potential therapeutic targets
for idiopathic inflammatory myopathies. Drug News Perspect
2006;19:549-557.
169 Authier FJ, Chariot P, Gherardi RK. Skeletal muscle involvement in
human immunodeficiency virus (HIV)-infected patients in the era of
highly active antiretroviral therapy (HAART). Muscle Nerve
2005;32:247-260.
170 Dalakas MC. Autoimmune muscular pathologies. Neurol Sci
2005;26(Suppl 1):S7-8.
171 Krivickas LS, Amato AA, Krishnan G et al. Preservation of in vitro
muscle fiber function in dermatomyositis and inclusion body
myositis: a single fiber study. Neuromuscul Disord
2005;15:349-354.
172 Ranque-Francois B, Maisonobe T, Dion E et al. Familial inflammatory
inclusion body myositis. Ann Rheum Dis 2005;64:634-637.
173 Caccamo A, Oddo S, Sugarman MC et al. Age- and region-dependent
alterations in Abeta-degrading enzymes: implications for Abeta-
induced disorders. Neurobiol Aging 2005;26:645-654.
174 Koudinov AR, Koudinova NV. Cholesterol homeostasis failure as a
unifying cause of synaptic degeneration. JN e u r o lS c i
2005;229-230:233-240.
175 Cafforio G, Pistolesi S, D’Avino C et al. Inclusion body myopathy
associated with motor neuron syndrome: three case reports. Clin
Neuropathol 2005;24:36-41.
176 Boros S, Kamps B, Wunderink L et al. Transglutaminase catalyzes
differential crosslinking of small heat shock proteins and amyloid-
beta. FEBS Lett 2004;576:57-62.
177 Gossrau G, Gestrich B, Koch R et al. Apolipoprotein E and alpha-1-
antichymotrypsin polymorphisms in sporadic inclusion body
myositis. Eur Neurol 2004;51:215-220.
178 Fidzianska A, Rowinska-Marcinska K, Hausmanowa-Petrusewicz I.
Coexistence of X-linked recessive Emery-Dreifuss muscular
dystrophy with inclusion body myositis-like morphology. Acta
Neuropathol (Berl) 2004;107:197-203.
179 Lampe JB, Gossrau G, Kempe A et al. Analysis of HLA class I and II
alleles in sporadic inclusion-body myositis. JN e u r o l
2003;250:1313-1317.
180 Nirmalananthan N, Holton JL, Hanna MG. Is it really myositis? A
consideration of the differential diagnosis. Curr Opin Rheumatol
2004;16:684-691.
181 Maurage CA, Bussiere T, Sergeant N et al. Tau aggregates are
abnormally phosphorylated in inclusion body myositis and have an
immunoelectrophoretic profile distinct from other tauopathies.
Neuropathol Appl Neurobiol 2004;30:624-634.
182 Price P, Santoso L, Mastaglia F et al. Two major histocompatibility
complex haplotypes influence susceptibility to sporadic inclusion
body myositis: critical evaluation of an association with HLA-DR3.
Tissue Antigens 2004;64:575-580.
183 Dalakas MC. The use of intravenous immunoglobulin in the
treatment of autoimmune neuromuscular diseases: evidence-based
indications and safety profile. Pharmacol Ther 2004;102:177-193.
184 Dalakas MC. Intravenous immunoglobulin in autoimmune
neuromuscular diseases. JAMA 2004;291:2367-2375.
1 8 5O l i v eM ,U n z e t aM ,M o r e n oD ,F e r r e rI .O v e r e x p r e s s i o no f
semicarbazide-sensitive amine oxidase in human myopathies.
Muscle Nerve 2004;29:261-266.
186 Bronner IM, Linssen WH, van der Meulen MF et al. Polymyositis: an
ongoing discussion about a disease entity. Arch Neurol
2004;61:132-135.
187 Tseng BP, Kitazawa M, LaFerla FM. Amyloid beta-peptide: the inside
story. Curr Alzheimer Res 2004;1:231-239.
188 Askanas V, Engel WK. Unicorns, dragons, polymyositis, and other
mythical beasts. Neurology 2004;63:403-404, author reply 404.
189 Chitnis T, Khoury SJ. 20. Immunologic neuromuscular disorders. J
Allergy Clin Immunol 2003;111:S659-668.
190 Askanas V, Engel WK, McFerrin J, Vattemi G. Transthyretin Val122Ile,
accumulatedAbeta,andinclusion-bodymyositisaspectsincultured
muscle. Neurology 2003;61:257-260.
191 Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet
2003;362:971-982.
192 Derk CT, Vivino FB, Kenyon L, Mandel S. Inclusion body myositis in
connective tissue disorders: case report and review of the literature.
Clin Rheumatol 2003;22:324-328.
193 MassawiG,HicklingP,HiltonD,PattersonC.Inclusionbodymyositis
evolving in systemic lupus erythrematosus? A case report.
Rheumatology (Oxford) 2003;42:1012-1014.
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 11 of 14194 Muntzing K, Lindberg C, Moslemi AR, Oldfors A. Inclusion body
myositis: clonal expansions of muscle-infiltrating T cells persist over
time. Scand J Immunol 2003;58:195-200.
195 Parissis D, Karkavelas G, Taskos N, Milonas I. Inclusion body
myositis in a patient with a presumed diagnosis of post-polio
syndrome. JN e u r o l2003;250:619-621.
196 Krause S, Schlotter-Weigel B, Walter MC et al. A novel homozygous
missense mutation in the GNE gene of a patient with quadriceps-
sparing hereditary inclusion body myopathy associated with muscle
inflammation. Neuromuscul Disord 2003;13:830-834.
197 Dalakas MC. High-dose intravenous immunoglobulin in
inflammatory myopathies: experience based on controlled clinical
trials. Neurol Sci 2003;24(Suppl 4):S256-259.
198 Tateyama M, Saito N, Fujihara K et al. Familial inclusion body
myositis: a report on two Japanese sisters. Intern Med
2003;42:1035-1038.
199 Fidzianska A, Kaminska A. Congenital myopathy with abundant ring
fibres, rimmed vacuoles and inclusion body myositis-type
inclusions. Neuropediatrics 2003;34:40-44.
200 Rutkove SB, Parker RA, Nardin RA et al. A pilot randomized trial of
oxandrolone in inclusion body myositis. Neurology
2002;58:1081-1087.
201 Kim SY, Jeitner TM, Steinert PM. Transglutaminases in disease.
Neurochem Int 2002;40:85-103.
202 Yazici Y, Kagen LJ. Clinical presentation of the idiopathic
inflammatory myopathies. Rheum Dis Clin North Am
2002;28:823-832.
203 vanderMeulenMF,HoogendijkJE,MoonsKGetal.Rimmedvacuoles
and the added value of SMI-31 staining in diagnosing sporadic
inclusion body myositis. Neuromuscul Disord 2001;11:447-451.
204 Phillips BA, Cala LA, Thickbroom GW et al. Patterns of muscle
involvement in inclusion body myositis: clinical and magnetic
resonance imaging study. Muscle Nerve 2001;24:1526-1534.
205 Felice KJ, North WA. Inclusion body myositis in Connecticut:
observations in 35 patients during an 8-year period. Medicine
(Baltimore) 2001;80:320-327.
206 Cherin P, Menard D, Mouton P et al. Macrophagic myofasciitis
associated with inclusion body myositis: a report of three cases.
Neuromuscul Disord 2001;11:452-457.
207A r n a r d o t t i rS ,A n s v e dT ,N e n n e s m oI ,B o r gK .R e p o r to fap a t i e n tw i t h
inclusion body myositis and CD8+ chronic lymphocytic leukaemia–
post-mortem analysis of muscle and brain. Acta Neurol Scand
2001;103:131-135.
208 Dalakas MC, Koffman B, Fujii M et al. A controlled study of
intravenous immunoglobulin combined with prednisone in the
treatment of IBM. Neurology 2001;56:323-327.
209 Ozden S, Gessain A, Gout O, Mikol J. Sporadic inclusion body
myositis in a patient with human T cell leukemia virus type 1-
associated myelopathy. Clin Infect Dis 2001;32:510-514.
210 Kieseier BC, Schneider C, Clements JM et al. Expression of specific
matrix metalloproteinases in inflammatory myopathies. Brain
2001;124:341-351.
211 Lampe JB, Walter MC, Reichmann H. Neurodegeneration-associated
proteins and inflammation in sporadic inclusion-body myositis. Adv
Exp Med Biol 2001;487:219-228.
212 Kovach MJ, Waggoner B, Leal SM et al. Clinical delineation and
localization to chromosome 9p13.3-p12 of a unique dominant
disorder in four families: hereditary inclusion body myopathy, Paget
disease of bone, and frontotemporal dementia. Mol Genet Metab
2001;74:458-475.
213 Muller-Felber W, Pongratz D, Reimers C. 64th ENMC International
Workshop: therapeutic approaches to dermatomyositis,
polymyositis, and inclusion body myositis29-31 January 1999,
Naarden, The Netherlands. Neuromuscul Disord 2001;11:88-92.
214 Yamada T, Minohara M, Imaiso Y et al. High-dose vitamin C therapy
for inclusion body myositis. Fukuoka Igaku Zasshi 2001;92:99-104.
215 Tsuruta Y, Yamada T, Yoshimura T et al. Inclusion body myositis
associated with hepatitis C virus infection. Fukuoka Igaku Zasshi
2001;92:370-376.
216 Fam AG. Recent advances in the management of adult myositis.
Expert Opin Investig Drugs 2001;10:1265-1277.
217 Fukuchi K, Li L, Hart M, Lindsey JR. Accumulation of amyloid-beta
protein in exocrine glands of transgenic mice overexpressing a
carboxyl terminal portion of amyloid protein precursor. Int J Exp
Pathol 2000;81:231-239.
218 Capsoni S, Ruberti F, Di Daniel E, Cattaneo A. Muscular dystrophy in
adult and aged anti-NGF transgenic mice resembles an inclusion
body myopathy. JN e u r o s c iR e s2000;59:553-560.
219 Bedlack RS, Strittmatter WJ, Morgenlander JC. Apolipoprotein E and
neuromusculardisease:acriticalreviewoftheliterature.ArchNeurol
2000;57:1561-1565.
220 Frederikse PH, Zigler SJ, Jr., Farnsworth PN, Carper DA. Prion protein
expression in mammalian lenses. Curr Eye Res 2000;20:137-143.
221 Askanas V, Engel WK, Alvarez RB et al. Inclusion body myositis,
muscle blood vessel and cardiac amyloidosis, and transthyretin
Val122Ile allele. Ann Neurol 2000;47:544-549.
222 Gayathri N, Anisya V, Veerendra Kumar M et al. Inclusion body
myositis (IBM). Clin Neuropathol 2000;19:13-20.
223 Amemiya K, Granger RP, Dalakas MC. Clonal restriction of T-cell
receptor expression by infiltrating lymphocytes in inclusion body
myositis persists over time. Studies in repeated muscle biopsies.
Brain 2000;123:2030-2039.
224 Grau JM, Perea M. Dermatomyositis with the features of inclusion
body myositis associated with carcinoma of the bladder: a true
association? Br J Dermatol 2000;143:671.
225 Boon AJ, Stolp-Smith KA. Inclusion body myositis masquerading as
polymyositis: a case study. Arch Phys Med Rehabil
2000;81:1123-1126.
226 Di Blasi C, Mora M, Pareyson D et al. Partial laminin alpha2 chain
deficiency in a patient with myopathy resembling inclusion body
myositis. Ann Neurol 2000;47:811-816.
227 Phillips BA, Zilko PJ, Mastaglia FL. Prevalence of sporadic inclusion
bodymyositisinWesternAustralia.MuscleNerve2000;23:970-972.
228 WalterMC,LochmullerH,ToepferMetal.High-doseimmunoglobulin
therapy in sporadic inclusion body myositis: a double-blind,
placebo-controlled study. JN e u r o l2000;247:22-28.
229 Nakayama T, Horiuchi E, Watanabe T et al. A case of inclusion body
myositis with benign monoclonal gammopathy successfully
responding to repeated immunoabsorption. JN e u r o lN e u r o s u r g
Psychiatry 2000;68:230-233.
230 Mirabella M, Christodoulou K, Di Giovanni S et al. An Italian family
with autosomal recessive quadriceps-sparing inclusion-body
myopathy (ARQS-IBM) linked to chromosome 9p1. Neurol Sci
2000;21:99-102.
231 Kuo YM, Kokjohn TA, Watson MD et al. Elevated abeta42 in skeletal
muscle of Alzheimer disease patients suggests peripheral
alterations of AbetaPP metabolism. Am J Pathol 2000;156:797-805.
232 Limaye V, Scott G, Kwiatek R, Pile K. Inclusion body myositis
associated with systemic lupus erythematosus (SLE). Aust N Z J Med
2000;30:275-276.
233 Guyer C. Recent developments in animal models of human
neurodegenerative diseases. Toxicol Pathol 2000;28:363-366.
234 Barohn RJ, Amato AA. Inclusion Body Myositis. Curr Treat Options
Neurol 2000;2:7-12.
235 Talanin NY, Bushore D, Rasberry R et al. Dermatomyositis with the
featuresofinclusionbodymyositisassociatedwithcarcinomaofthe
bladder. Br J Dermatol 1999;141:926-930.
236 Nakano S, Akiguchi I, Nakamura S et al. Aberrant expression of
cyclin-dependent kinase 5 in inclusion body myositis. Neurology
1999;53:1671-1676.
237 Kok CC, Croager EJ, Witt CS et al. Mapping of a candidate region for
susceptibility to inclusion body myositis in the human major
histocompatibility complex. Immunogenetics 1999;49:508-516.
238 LampeJ,KitzlerH,WalterMCetal.Methioninehomozygosityatprion
gene codon 129 may predispose to sporadic inclusion-body
myositis. Lancet 1999;353:465-466.
239 VillanovaM,CeuterickC,DottiMTetal.Detectionofbeta-A4amyloid
and its precursor protein in the muscle of a patient with juvenile
neuronal ceroid lipofuscinosis (Spielmeyer-Vogt-Sjogren). Acta
Neuropathol (Berl) 1999;98:78-84.
240 McCoy AL,Bubb MR, Plotz PH, DavisJC. Inclusion body myositislong
after dermatomyositis: a report of two cases. Clin Exp Rheumatol
1999;17:235-239.
241 MastagliaFL,PhillipsBA,ZilkoPJ.InflammatoryMyopathy.CurrTreat
Options Neurol 1999;1:263-272.
242 FyhrIM,MoslemiAR,LindbergC,OldforsA.Tcellreceptorbeta-chain
repertoire in inclusion body myositis. J Neuroimmunol
1998;91:129-134.
243 Levine TD, Pestronk A. Inflammatory myopathy with cytochrome
oxidase negative muscle fibers: methotrexate treatment. Muscle
Nerve 1998;21:1724-1728.
244 Lodi R, Taylor DJ, Tabrizi SJ et al. Normal in vivo skeletal muscle
oxidative metabolism in sporadic inclusion body myositis assessed
by 31P-magnetic resonance spectroscopy. Brain
1998;121:2119-2126.
245 Koffman BM, Sivakumar K, Simonis T et al. HLA allele distribution
distinguishes sporadic inclusion body myositis from hereditary
inclusion body myopathies. JN e u r o i m m u n o l1998;84:139-142.
246 Bender A, Behrens L, Engel AG, Hohlfeld R. T-cell heterogeneity in
muscle lesions of inclusion body myositis. JN e u r o i m m u n o l
1998;84:86-91.
247 van der Meulen MF, Hoogendijk JE, Jansen GH et al. Absence of
characteristic featuresin two patients with inclusion body myositis. J
Neurol Neurosurg Psychiatry 1998;64:396-398.
248 Tome FM, Fardeau M. Hereditary inclusion body myopathies. Curr
Opin Neurol 1998;11:453-459.
RESEARCH
page 12 of 14 BMJ | ONLINE FIRST | bmj.com249 Darin N, Kyllerman M, Wahlstrom J et al. Autosomal dominant
myopathy with congenital joint contractures, ophthalmoplegia, and
rimmed vacuoles. Ann Neurol 1998;44:242-248.
250 Oyama F, Murakami N, Ihara Y. Chloroquine myopathy suggests that
tauisdegradedin lysosomes:implication fortheformation ofpaired
helical filaments in Alzheimer’sd i s e a s e .Neurosci Res 1998;31:1-8.
251 Yang CC, Alvarez RB, Engel WK et al. Nitric oxide-induced oxidative
stress in autosomal recessive and dominant inclusion-body
myopathies. Brain 1998;121:1089-1097.
252 Horvath R, Fu K, Johns T et al. Characterization of the mitochondrial
DNA abnormalities in the skeletal muscle of patients with inclusion
body myositis. J Neuropathol Exp Neurol 1998;57:396-403.
253 Amato AA, Shebert RT. Inclusion body myositis in twins. Neurology
1998;51:598-600.
254 Dalakas MC. Controlled studies with high-dose intravenous
immunoglobulininthetreatmentofdermatomyositis,inclusionbody
myositis, and polymyositis. Neurology 1998;51(6 Suppl 5):S37-45.
255 Querfurth HW, Jiang J, Geiger JD, Selkoe DJ. Caffeine stimulates
amyloid beta-peptide release from beta-amyloid precursor protein-
transfected HEK293 cells. JN e u r o c h e m 1997;69:1580-1591.
256 Sivakumar K, Semino-Mora C, Dalakas MC. An inflammatory,
familial, inclusion body myositis with autoimmune features and a
phenotype identical to sporadic inclusion body myositis. Studies in
three families. Brain 1997;120:653-661.
257 DalakasMC,SoniesB,DambrosiaJetal.Treatmentofinclusion-body
myositis with IVIg: a double-blind, placebo-controlled study.
Neurology 1997;48:712-716.
258 Brannagan TH, Hays AP, Lange DJ, Trojaborg W. The role of
quantitative electromyography in inclusion body myositis. JN e u r o l
Neurosurg Psychiatry 1997;63:776-779.
259 Fyhr IM, Moslemi AR, Mosavi AA et al. Oligoclonal expansion of
muscleinfiltratingTcellsininclusionbodymyositis.JNeuroimmunol
1997;79:185-189.
260 Spector SA, Lemmer JT, Koffman BM et al. Safety and efficacy of
strength training in patients with sporadic inclusion body myositis.
Muscle Nerve 1997;20:1242-1248.
2 6 1P r a y s o nR A ,C o h e nM L .U b i q u i t i ni m m u n o s t a i n i n ga n di n c l u s i o n
body myositis: study of 30 patients with inclusion body myositis.
Hum Pathol 1997;28:887-892.
262 Mastaglia FL, Phillips BA, Zilko P. Treatment of inflammatory
myopathies. Muscle Nerve 1997;20:651-664.
263 Jensen ML, Wieting JM, Andary MT et al. Inclusion body myositis and
transitional cell carcinoma of the bladder: significant resolution of
symptoms after tumor excision. Arch Phys Med Rehabil
1997;78:327-329.
264 Dalakas MC, Illa I, Gallardo E, Juarez C. Inclusion body myositis and
paraproteinemia: incidence and immunopathologic correlations.
Ann Neurol 1997;41:100-104.
265 Askanas V. New developments in hereditary inclusion body
myopathies. Ann Neurol 1997;41:421-422.
266 Authier FJ, Mhiri C, Chazaud B et al. Interleukin-1 expression in
inflammatory myopathies: evidence of marked immunoreactivity in
sarcoid granulomas and muscle fibres showing ischaemic and
regenerative changes. Neuropathol Appl Neurobiol
1997;23:132-140.
267 Sekul EA, Chow C, Dalakas MC. Magnetic resonance imaging of the
forearm as a diagnostic aid in patients with sporadic inclusion body
myositis. Neurology 1997;48:863-866.
268 Barohn RJ. The therapeutic dilemma of inclusion body myositis.
Neurology 1997;48:567-568.
269 Robertson TA, Dutton NS, Martins RN et al. Beta-amyloid protein-
containing inclusions in skeletal muscle of apolipoprotein-E-
deficient mice. Am J Pathol 1997;150:417-427.
270 Luciano CA, Dalakas MC. Inclusion body myositis: no evidence for a
neurogenic component. Neurology 1997;48:29-33.
271 Cupler EJ, Leon-Monzon M, Miller J et al. Inclusion body myositis in
HIV-1 and HTLV-1 infected patients. Brain 1996;119:1887-1893.
272 Sivakumar K, Dalakas MC. The spectrum of familial inclusion body
myopathies in 13 families and a description of a quadriceps-sparing
phenotype in non-Iranian Jews. Neurology 1996;47:977-984.
273 De Bleecker JL, Engel AG, Ertl BB. Myofibrillar myopathy with
abnormal foci of desmin positivity. II. Immunocytochemical analysis
reveals accumulation of multiple other proteins. J Neuropathol Exp
Neurol 1996;55:563-577.
274 Love S, Nicoll JA, Lowe J, Sherriff F. Apolipoprotein E allele
frequencies in sporadic inclusion body myositis. Muscle Nerve
1996;19:1605-1607.
275 Amato AA, Gronseth GS, Jackson CE et al. Inclusion body myositis:
clinical and pathological boundaries. Ann Neurol 1996;40:581-586.
276 Askanas V, Engel WK, Mirabella M et al. Apolipoprotein E alleles in
sporadic inclusion-body myositis and hereditary inclusion-body
myopathy. Ann Neurol 1996;40:264-265.
277 Santorelli FM, Sciacco M, Tanji K et al. Multiple mitochondrial DNA
deletionsinsporadicinclusionbodymyositis:astudyof56patients.
Ann Neurol 1996;39:789-795.
278 Felice KJ, Grunnet ML. Inclusion body myositis associated with a
severe unilateral levodopa-responsive upper extremity tremor.
Muscle Nerve 1996;19:787-789.
279 Dalakas MC. Clinical benefits and immunopathological correlates of
intravenous immune globulin in the treatment of inflammatory
myopathies. Clin Exp Immunol 1996;104(Suppl 1):55-60.
280 NaumannM,ReichmannH,GoebelHHetal.Glucocorticoid-sensitive
hereditary inclusion body myositis. JN e u r o l1996;243:126-130.
281 Mirabella M, Alvarez RB, Bilak M et al. Difference in expression of
phosphorylated tau epitopes between sporadic inclusion-body
myositis and hereditary inclusion-body myopathies. JN e u r o p a t h o l
Exp Neurol 1996;55:774-786.
282 Askanas V, Engel WK. Response to Letter from Rosenblum, W. I.: Two
distinct forms of hyperphosphorylated tau in sporatic versus
hereditary inclusion myopathy. J Neuropathol Exp Neurol
1996;55:1179-1180.
283 Fiori MG, Salvi F, Plasmati R, Tassinari CA. Muscle fiber splitting,
capillary internalization, and target-like fiber formation in familial
amyloidotic polyneuropathy. Clin Neuropathol 1996;15:240-247.
284 Kagen LJ. New developments in the myositis syndromes. Bull Rheum
Dis 1996;45:1-4.
285 Garlepp MJ, Tabarias H, van Bockxmeer FM et al. Apolipoprotein E
epsilon 4 in inclusion body myositis. Ann Neurol 1995;38:957-959.
286 Nadkarni N, Freimer M, Mendell JR. Amyloidosis causing a
progressive myopathy. Muscle Nerve 1995;18:1016-1018.
287 Barohn RJ, Amato AA, Sahenk Z et al. Inclusion body myositis:
explanation for poor response to immunosuppressive therapy.
Neurology 1995;45:1302-1304.
288 Murakami N, Ihara Y, Nonaka I. Muscle fiber degeneration in distal
myopathy with rimmed vacuole formation. Acta Neuropathol (Berl)
1995;89:29-34.
289 CohenAS.Clinicalaspectsofamyloidosis,includingrelatedproteins
and central nervous system amyloid. Curr Opin Rheumatol
1994;6:68-77.
290 HarringtonCR,AndersonJR,ChanKK.ApolipoproteinEtypeepsilon4
allele frequency is not increased in patients with sporadic inclusion-
body myositis. Neurosci Lett 1995;183:35-38.
291 Dalakas MC. Update on the use of intravenous immune globulin in
the treatment of patients with inflammatory muscle disease. J Clin
Immunol 1995;15(6 Suppl):70S-75S.
292 Dalakas MC, Illa I. Common variable immunodeficiency and
inclusion body myositis: a distinct myopathy mediated by natural
killer cells. Ann Neurol 1995;37:806-810.
293 Dasque F, Laroche M, Marque P et al. Isokinetic strength testing for
evaluating the efficacy of intravenous immune globulin therapy for
inclusion body myositis. Rev Rhum Engl Ed 1995;62:598-601.
294 Tsuzuki K, Fukatsu R, Takamaru Y et al. Co-localization of amyloid-
associated proteins with amyloid beta in rat soleus muscle in
chloroquine-induced myopathy: a possible model for amyloid beta
f o r m a t i o ni nA l z h e i m e r ’sd i s e a s e .Brain Res 1995;699:260-265.
295 Garlepp MJ, Laing B, Zilko PJ et al. HLA associations with inclusion
body myositis. Clin Exp Immunol 1994;98:40-45.
296 Tsuzuki K, Fukatsu R, Takamaru Y et al. Immunohistochemical
evidence for amyloid beta in rat soleus muscle in chloroquine-
induced myopathy. Neurosci Lett 1994;182:151-154.
297 Gambetti P, Perry G. Alzheimer’s disease and prion proteins: a
meeting made in muscle. Am J Pathol 1994;145:1261-1264.
298 Akaaboune M, Ma J, Festoff BW et al. Neurotrophic regulation of
mouse muscle beta-amyloid protein precursor and alpha 1-
antichymotrypsin as revealed by axotomy. JN e u r o b i o l
1994;25:503-514.
299 DeArmond SJ. Alzheimer’s disease and Creutzfeldt-Jakob disease:
overlap of pathogenic mechanisms. Curr Opin Neurol
1993;6:872-881.
300 HopkinsonND,HuntC,PowellRJ,LoweJ.Inclusionbodymyositis:an
underdiagnosed condition? Ann Rheum Dis 1993;52:147-151.
301 Beyenburg S, Zierz S, Jerusalem F. Inclusion body myositis: clinical
and histopathological features of 36 patients. Clin Investig
1993;71:351-361.
302 Askanas V, Engel WK, Alvarez RB. Strong immunoreactivity of beta-
amyloid precursor protein, including the beta-amyloid protein
sequence, at human neuromuscular junctions. Neurosci Lett
1992;143:96-100.
303 Wikipedia, the free encyclopedia. Network theory. http://en.
wikipedia.org/wiki/Network_theory (accessed 24 Jan 2009).
304 Wikipedia, the free encyclopedia. Centrality. http://en.wikipedia.
org/wiki/Centrality (accessed 24 Jan 2009).
305 Newman MEJ. A measure of betweenness centrality based on
random walks. Social Networks
2005;27:39-54. http://arxiv.org/PS_cache/cond-mat/pdf/0309/
0309045v1.pdf (accessed 24 Jan 2009).
306 Kleinberg JM. Authoritative sources in a hyperlinked environment.
Proceedings of the ACM-SIAM symposium on discrete algorithms,
1998:668-77. www.cs.cornell.edu/home/kleinber/auth.pdf
(accessed 24 Jan 2009).
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 13 of 14307 Clauset A, Shalizi CR, Newman MEJ. Power-law distributions in
empirical data. http://arxiv.org/PS_cache/arxiv/pdf/0706/
0706.1062v1.pdf (accessed 24 Jan 2009).
308 Newman MEJ Assortativity mixing in networks. Phys Rev Lett
2002;89:208701. Retrieved January 24, 2009 from http://arxiv.org/
PS_cache/cond-mat/pdf/0205/0205405v1.pdf (accessed 24 Jan
2009).
309 Wikipedia, the free encyclopedia. Social networks. http://en.
wikipedia.org/wiki/Social_network (accessed 24 Jan 2009).
310 NationalInstitutesofHealthFreedomofInformationActOffice.www.
nih.gov/icd/od/foia/index.htm
311 Hyland K. Self-citation and self-reference: credibility and promotion
in academic publication. J Am Soc Inform Sci Technol
2003;54:251-9.
312 Gilbert GN. Referencing as persuasion. Soc Stud Sci
1977;7:113-22. www.jstor.org/stable/284636 (accessed 28 Feb
2009).
313 Garfield E. Citation indexes for science. Science 1955;122:108-11.
314 Dickersin K. Reporting and other biases in studies of Neurontin for
migraine, psychiatric/bipolar disorders, nociceptive pain, and
neuropathic pain. http://dida.library.ucsf.edu/pdf/oxx18r10
(accessed 28 Feb 2009).
315 Hengstman GJD, van Engelen BGM. Polymyositis, invasion of non-
necrotic muscle fibres, and the art of repetition. BMJ
2004;329:1464-7.
316 Bikhchandani S, Hirshleifer D, Welch I. A theory of fads, fashion,
custom, and cultural change as informational cascades. JP o l i t i c a l
Econ 1992;100:992-1026.
317 Banerjee AH. A simple model of herd behavior. Quart J Econ
1992;107:797-817.
318 Tatsioni A, Bonitsis NG, Ioannidis JPA. Persistence of contradicted
claims in the literature. JAMA 2007;298:2517-26.
319 Wikipedia, the free encyclopedia. Publication bias. http://en.
wikipedia.org/wiki/Publication_bias (accessed 24 Jan 2009).
320 HowtoWriteaResearchGrant.GuidelinesfromtheNationalInstitute
of Neurological Disorders and Stroke. www.ninds.nih.gov/funding/
write_grant_doc.htm (accessed 24 Jan 2009).
321 Wikipedia, the free encyclopedia. Confirmation bias. http://en.
wikipedia.org/wiki/Confirmation_bias (accessed 24 Jan 2009).
Accepted: 17 March 2009
RESEARCH
page 14 of 14 BMJ | ONLINE FIRST | bmj.com